ESMO Clinical Practice Guidelines: Head And Neck Cancers

• ESMO
• Meeting Calendar
• OncologyPRO

• About ESMO
  • ESMO Vision 2025
    • One Oncology Community
    • Education for Life
    • Accessible Cancer Care
  • ESMO Mission
  • ESMO Values
  • Awards
    • ESMO Award Nominations
    • Fellow of ESMO (FESMO)
      • FESMO 2023
      • FESMO 2022
    • ESMO Award
    • ESMO Award for Translational Research
    • ESMO Women for Oncology Award
    • ESMO Lifetime Achievement Award
    • ESMO Breast Cancer Award
    • Heine H. Hansen Award
    • ESMO Award for Immuno-Oncology
    • TAT Honorary Award
  • Organisational Structure
    • ESMO Council
    • Executive Board
    • Annals of Oncology Editorial Board
    • Audit Committee
    • Cancer Medicines Committee
    • Communication Committee
    • Compliance Committee
    • Educational Committee
      • Adolescents and Young Adults Working Group
      • Designated Centres Working Group
      • Educational Publications Working Group
      • ESMO Faculty
      • ESMO Precision Oncology Working Group
      • ESMO SIOG Cancer in the Elderly Working Group
      • Examination & Accreditation Working Group
      • OncologyPRO Working Group
      • Practising Oncologists Working Group
      • Real World Data and Digital Health Working Group
    • ESMO Faculty
    • ESMO Gastrointestinal Oncology Editorial Board
    • ESMO Industry Strategic Forum
    • ESMO Members: Get Involved
      • Volunteer with ESMO
    • ESMO Open Editorial Board
    • ESMO Real World Data and Digital Oncology Editorial Board
    • ESMO Task Forces
      • ESMO Gender Medicine Task Force
      • Climate Change Task Force
      • Resilience Task Force
      • ESMO Clinical Research Observatory Task Force (ECRO)
    • Guidelines Committee
      • ESMO-Magnitude of Clinical Benefit Scale Working Group
      • Major Achievements
    • IOTECH Editorial Board
    • Leadership Development Committee
    • Membership Committee
    • National Societies Committee
    • Nomination Committee
    • Women for Oncology Committee
    • Young Oncologists Committee
      • Major Achievements
  • How we work
    • Declaration of Interest
      • EFPIA Disclosure Code
    • ESMO Presidential Election: 2027-2028
      • ESMO Elections FAQ
    • ESMO Structure
    • Code of Conduct
    • ESMO Annual Report
    • ESMO Funding
      • 2019 Funding Sources
      • 2020 Funding Sources
      • 2021 Funding Sources
      • 2022 Funding Sources
      • 2023 Funding Sources
    • ESMO Bylaws
    • General Assembly
      • Notice of the 2024 Ordinary Annual General Assembly Vote
  • Biographies
  • Careers at ESMO
  • Discover ESMO Journals
    • Annals of Oncology
      • About Annals of Oncology
      • Annals of Oncology 35th Anniversary
    • ESMO Open
      • Frequently Asked Questions
    • Immuno-Oncology and Technology
    • ESMO Gastrointestinal Oncology
    • ESMO Real World Data and Digital Oncology
    • ESMO Affiliated Journals
      • Cancer Treatment Reviews
      • Clinical Lymphoma Myeloma and Leukemia
      • Lung Cancer
      • The Breast
    • ESMO Rare Cancers
    • COVID-19 and cancer care in the ESMO journals
  • ESMO Brand
    • ESMO Logo
  • Collaborate with ESMO
    • Frequently Asked Questions
  • President Letter
    • Stepping into the shoes of a Society with a global footprint
    • Embracing a year of strong collaboration and steady progress
    • Looking ahead, honouring the past
  • Joining Forces
    • ESMO for World Cancer Day 2024
    • ESMO for World Cancer Day 2023
    • ESMO for World Cancer Day 2022
    • ESMO for World Cancer Day 2021
    • ESMO for World Cancer Day 2020
  • Contact Us
• Membership
  • Join ESMO
  • Member Benefits
  • Membership Categories & Annual Fees
• Guidelines
  • Guidelines by topic
    • Breast Cancer
    • Cancers of Unknown Primary Site
    • Endocrine and Neuroendocrine Cancers
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Gynaecological Cancers
    • Haematological Malignancies
    • Head and Neck Cancers
    • Hereditary Syndromes
    • Lung and Chest Tumours
    • Melanoma and Skin Cancers
    • Neuro-Oncology
    • Sarcoma and GIST
    • Supportive and Palliative Care
  • Guidelines News
  • ESMO Expert Consensus Statements
  • Pan-Asian Guidelines Adaptation (PAGA)
  • ESMO Guidelines Methodology
  • Pocket Guidelines & Mobile App
    • Translated ESMO Pocket Guidelines
  • Guidelines Slide Sets
  • Cancer Patient Management During the COVID-19 Pandemic
    • Disclaimer
    • Primary brain tumours in the COVID-19 era
    • Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era
    • Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era
    • Genitourinary cancers: Renal cell cancer in the COVID-19 era
    • Genitourinary cancers: Prostate cancer in the COVID-19 era
    • Gynaecological malignancies: Cervical cancer in the COVID-19 era
    • Gynaecological malignancies: Endometrial cancer in the COVID-19 era
    • Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA)
    • Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA)
    • Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA)
    • Haematological malignancies: Multiple myeloma in the COVID-19 era
    • Head and neck cancers in the COVID-19 era
    • Melanoma in the COVID-19 era
    • Sarcomas in the COVID-19 era
    • Supportive Care in the COVID-19 era
  • COVID-19 Palliative Care Pathways
  • Q&A on COVID-19
  • COVID-19 adapted recommendations Slide Sets
  • ESMO-MCBS
    • ESMO-MCBS Online Tutorials
    • About the ESMO-MCBS
    • ESMO-MCBS in Action
    • ESMO-MCBS sessions at ESMO 2020
    • ESMO-MCBS for Solid Tumours
    • ESMO-MCBS for Haematological Malignancies
    • ESMO-MCBS Terms of Use
• Meetings
  • Meeting Calendar
    • Past Meetings
  • ESMO Congresses
  • ESMO Virtual Plenaries
    • Sponsors
  • ESMO Academy
  • ESMO Advanced Courses
    • FAQs
    • Acknowledgements
    • Testimonials
  • ESMO Preceptorship Courses
    • Acknowledgements
    • FAQs
    • Testimonials
  • ESMO Summits
    • Testimonials
  • ESMO Courses in Medical Oncology for Medical Students
    • ESMO Best Student Award
    • Testimonials
  • ESO-ESMO Masterclasses
  • ESMO Symposia
  • ESMO Colloquia
  • ESMO Webinar Series
  • Workshops
  • ESMO Events App
    • How to Use the App
  • ESMO Licensed Events
• Career Development
  • Oncology Fellowships
    • Host Institutes
    • Host an ESMO Fellow
    • Fellowship Offers
    • Benefits for Institutes
    • Awardees and Reports
    • External Oncology Fellowship Opportunities
    • About Oncology Fellowships
  • Resilience Task Force
    • ESMO Resilience Task Force: Survey Series
  • Young Oncologists Corner
    • Young Oncologists Track
    • Research MATCH
    • YO4YO Virtual Session Series
    • About Young Oncologists Corner
    • National Activities
    • Considering a Career Abroad?
  • ESMO Examination
    • Parallel Sessions
    • Why Sit the ESMO Exam?
    • ESMO Exam Talent Pool
    • Sample Exam Questions Explained
    • Best Exam Award
  • Recertification & CME
    • ESMO-MORA Recertification Process and Requirements
    • CME Tests for Handbooks
  • ESMO Certificate of Professional Development
    • ESMO Advanced Courses
    • ESMO Preceptorship Courses
    • ESMO Webinar Series
    • ESMO Virtual Plenaries
  • Jobs in Oncology
    • H.U.B - Professor in Immuno-Oncology - Full-time (h/f/x), Hôpital Universitaire de Bruxelles, Belgium
  • Women for Oncology
    • ESMO W4O Observatory
    • W4O Hub
    • Resource Centre
    • W4O Sessions and Events
  • Leaders Generation Programme
    • Class of 2021-2022
    • Class of 2016
    • Class of 2017
    • Class of 2018
    • Class of 2019
  • Leaders Generation Programme Asia
    • Class of 2019
    • Class of 2022
  • Travel Grants for ESMO Meetings
  • About Career Development
• Scales and Tools
  • ESMO Guidance for Reporting Oncology real-World Evidence (ESMO-GROW)
  • ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
  • ESMO-MCBS
• Research
  • About the Grant Schemes
  • ESMO Clinical Research Observatory Task Force (ECRO)
    • Acknowledgements: Rationalizing Bureaucracy
    • Bibliography on Clinical Trial Procedures
  • Research Funding opportunities
    • ESMO Webinar: EU Research Opportunities
    • How to Apply For EU Grants
    • EU Calls for Proposals
    • Training and Events
    • Regulatory Information
    • Other Research Funding Opportunities
  • Research Groups, Tools and Database
    • General research groups
    • Cancer research groups by type
    • Databases
    • Research tools
  • COVID-19 and Cancer: Registries, Studies and Surveys
    • ESMO-CoCARE Registry
• For Patients
  • ESMO Designated Centres of Integrated Oncology and Palliative Care
    • Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris
    • Designated Centres Working Group
    • Palliative and Supportive Care Sessions at ESMO Congress 2023 Madrid
    • 2024 ESMO Designated Centres
    • Palliative and Supportive Care Sessions at ESMO Congress 2024 Barcelona
  • Resources for Patients with Cancer
  • Cancer Care During the COVID-19 Pandemic
    • Multiple Myeloma
    • Melanoma
    • Sarcoma
    • Krebstherapie während der COVID-19-Pandemie
    • Renal Cell Carcinoma
    • Prostate Cancer
    • Pancreatic Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Supportive Care Glossary
    • Palliative Care Glossary
    • Gastro-Oesophageal Cancer
    • Hepatocellular Carcinoma
    • Endometrial Cancer
    • Colorectal Cancer
    • Primary Brain Tumour
    • Aggressive Lymphoma Management
    • Breast Cancer
    • B-cell non-Hodgkin Lymphoma
    • Urothelial Bladder Cancer
    • Hodgkin Lymphoma
    • Cervical Cancer
    • Traitement du Cancer au Cours de la Pandémie de COVID-19
    • Le Cure per il Cancro Durante la Pandemia da COVID-19
    • Cuidado del cáncer durante la pandemia de COVID-19
    • Glossary
  • Patient Advocates Working Group
    • Call for Applications
  • Patient Advocacy Track
  • Patient Guides
    • Patient Guides by Language
    • Bone Health in Cancer
    • Immunotherapy Side Effects
    • Survivorship
    • Cancer Pain Management
    • Personalised Cancer Medicine
  • Personalised Medicine Explained
  • Getting the Most out of Your Oncologist
  • ESMO Patient Engagement Summit
    • ESMO Patient Engagement Summit 2024: Call to Action
• Policy
  • ESMO Manifesto
  • Policy News
  • Public Policy Committee
  • Patient Advocates Working Group
  • Cancer Medicines Committee
  • ESMO Public Policy Track and Special Sessions
• Newsroom
  • Press and Media Hub
  • ESMO Daily Reporter
  • Oncology News
  • ESMO Society Updates

• Login

Latest enhanced and revised set of guidelines

These guidelines on Nasopharyngeal cancer, Salivary gland cancer and Squamous cell carcinoma of the head and neck include information on incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up.

The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine.

• Patient Guide
• Webcast

• Pan-Asian Adaptation
• Patient Guide
• Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

• Necessary cookies

  Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.